ReviewFrontiers in immunology2025
Regulatory mechanisms of Th9 cell differentiation.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Molecular Signature and miRNA Pattern of CD4 + T Lymphocytes in Plaque Psoriasis.Clinical reviews in allergy & immunology · 2026Review
- A Leap Forward in Vaccination - the Epigenetic Silencing of HIV by cVacc.Current HIV/AIDS reports · 2026Review
- Cuproptosis of bronchial epithelial cells triggers airway remodeling in chronic asthma.Scientific reports · 2026Article
- Genetically Predicted 12,13-DiHOME Mediates the Association between TNF-Related Apoptosis-Inducing Ligand and Immune Thrombocytopenia.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Interplay between microRNAs and TGF-β signaling in T cells: implications for Th9 differentiation and immune pathogenesis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Th9 cells, a distinct subset of T helper cells, are defined by their production of IL-9. Th9 cells play a role in the development of various diseases by participating in mucosal immune responses, defending tissue barriers, and regulating inflammatory responses. For instance, Th9 cells contribute to inflammatory bowel disease by secreting IL-9, which damages the intestinal epithelial barrier. The effects mediated by Th9-derived IL-9 exhibit environment-dependent characteristics. In allergic asthma, IL-9 drives inflammation, while in specific tumor microenvironments, IL-9 can exert anti-tumor effects. Th9 cell differentiation is governed by a complex, multi-layered regulatory network. This network centers on the synergistic action of transforming growth factor-beta (TGF-β) and interleukin-4 (IL-4). Additionally, it involves multiple other mechanisms. These include exogenous signals such as IL-2 and IL-35; intrinsic transcription factors like the ATF-like protein BATF and PU.1; epigenetic modifications, including histone acetylation and DNA methylation; and metabolic reprogramming, such as glycolysis and lipid metabolism, among others. This review systematically summarizes the regulatory mechanisms governing Th9 cell differentiation. It elucidates these mechanisms and reveals potential therapeutic targets, including transcription factors such as PU.1, IRF4, and BATF. This work paves the way for the development of Th9-related immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.